Veracyte: Core Growth Funds Prosigna And TrueMRD

Impact · against what's priced in

VCYT shares have significant upside potential because 2026 financial guidance completely excludes revenue from the Prosigna and TrueMRD launches. Strong Q2 growth and a debt-free balance sheet provide a stable foundation for this unpriced expansion.

VCYT+0.60: No priced-in read yet
In context: The exclusion of Prosigna and TrueMRD contributions from 2026 guidance creates a clear catalyst for revenue growth beyond current expectations, supported by a 29.2% EBITDA margin and zero funded debt.
Read from the article alone

Veracyte: Core Growth Funds Prosigna And TrueMRD

revenue growth▲8%
guidance▲7%
earnings▲2%
healthcare
biotech
VCYT
cancer diagnostics

Veracyte: Core Growth Funds Prosigna And TrueMRD

What matters in this story

KLA: Unfairly Caught Up In The Tech Carnage

Veracyte: Core Growth Funds Prosigna And TrueMRD

What matters in this story

KLA: Unfairly Caught Up In The Tech Carnage

How each ticker is affected

Track these names every morning.

MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last?

HMN Q3 Earnings Call Highlights Higher Outlook and Profitability

EL's Fiscal 2030 Roadmap Targets Stronger Growth & Higher Margins

Sandisk: A 35% Stock Decline, But RPO Tells A Different Story (Rating Upgrade)

Veracyte: Core Growth Funds Prosigna And TrueMRD

What matters in this story

Next reads from the same story arc

KLA: Unfairly Caught Up In The Tech Carnage

Veracyte: Core Growth Funds Prosigna And TrueMRD

What matters in this story

Next reads from the same story arc

KLA: Unfairly Caught Up In The Tech Carnage

How each ticker is affected

Track these names every morning.

MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last?

HMN Q3 Earnings Call Highlights Higher Outlook and Profitability

EL's Fiscal 2030 Roadmap Targets Stronger Growth & Higher Margins

Sandisk: A 35% Stock Decline, But RPO Tells A Different Story (Rating Upgrade)